GlaxoSmithKline PLC | Financial Times

Wednesday, 5 February, 2020

GSK warns profits to fall as it steps up R&D spending

UK drugmaker weighs asset sales to help cover costs of planned break-up

Thursday, 30 January, 2020

EU court backs UK regulator on GSK ‘pay-for-delay’ fine

Deals with rivals to delay generic versions have potential to prevent future price cuts

Wednesday, 22 January, 2020

GlaxoSmithKline censured by EU over pay-for-delay deals

Legal opinion ahead of ECJ ruling supports CMA fine over delayed launch of antidepressant

Monday, 20 January, 2020

GSK and genetic testing group 23andMe seek first drug target

UK drugmaker hopes to launch clinical trial by end of the year

Wednesday, 30 October, 2019

GSK raises outlook again amid strong demand for shingles drug

UK drugmaker also boosted by performance of consumer health and vaccines divisions

Monday, 21 October, 2019

GSK agrees €1bn sale of two vaccines

UK drugmaker offloads assets as it focuses on profitable and new products

Saturday, 28 September, 2019

Pharmaceuticals sector

Data may widen market for ovarian cancer drugs

Clinical trials show gains in the battle for frontline treatments

Sunday, 25 August, 2019

UK tax

HMRC targets GSK contractors in tax crackdown

Almost 1,500 self-employed workers receive letters questioning their job status

Wednesday, 24 July, 2019

Pharmaceuticals sector

GSK lifts outlook after vaccines drive strong quarter

Shingles and meningitis treatments help offset blow from generic version of key drug

Promoted Content

Wednesday, 24 July, 2019

Lex

GSK: betting the pharm Premium

Bold decisions being taken by chief executive Emma Walmsley should pay off

Wednesday, 24 July, 2019

Drugs research

GSK market hopes boosted by two-drug HIV trial

Dovato shown to be as effective as Gilead’s traditional combination treatment

Saturday, 20 July, 2019

GSK sets out plan to double drug discovery success

Staff encouraged to take more risks in pursuit of blockbuster medicines

Monday, 15 July, 2019

Ovarian cancer treatment boosts GSK

UK drugmaker has been under pressure to produce new money-spinning medicines

Sunday, 14 July, 2019

GSK to appoint Jonathan Symonds as chairman

HSBC deputy chair and former Astra finance chief to oversee break-up of UK pharma group

Thursday, 13 June, 2019

Genomics

GSK links up with US university on genome research

Drugmaker will fund 20 scientists in rare partnership with University of CaliforniaS

Thursday, 23 May, 2019

GSK revamps incentives for sales representatives

Drugmaker to link bonuses to number of prescriptions written for its medicines

Wednesday, 1 May, 2019

GSK sales boosted by shingles and HIV treatments success

Group beats expectations but warns generic alternative will hit best-selling asthma drug

Wednesday, 24 April, 2019

Disease control and prevention

Malawi starts pilot of malaria vaccine for children

GSK drug to be piloted as part of landmark project across Africa

Friday, 12 April, 2019

City InsiderPatrick Jenkins

Hampton all at sea over next move

City veteran plans to keep on sailing after transatlantic crossing

Monday, 8 April, 2019

Drugs research

GSK two-drug/one-pill HIV treatment given FDA approval

Clinical trials show reduced regimen still effective at controlling virus

Thursday, 7 March, 2019

Pharmaceuticals sector

Monthly jab for HIV treatment passes late-stage trials

ViiV Healthcare regimen hoped to offer less toxic alternative to daily tablets

Friday, 22 February, 2019

AnalysisSerious Fraud Office UK

SFO abandons cases as new chief tackles backlog

Lengthy inventory of longstanding investigations prompts tough decisions

Friday, 22 February, 2019

Serious Fraud Office UK

SFO ends investigations into Rolls-Royce and GSK

Two of the anti-fraud agency’s biggest and longest-running cases are brought to a close

Wednesday, 6 February, 2019

GSK strategy revamp and shingles drug help lift earnings

UK drugmaker warns 2019 earnings likely to be hit by generic rival to Advair asthma drug

Tuesday, 5 February, 2019

Pharmaceuticals sector

GSK acquires rights to new Merck cancer treatment

UK group to pay up to €3.7bn to co-develop novel class of immunology

Add to myFT Digest